Loading

Journal of Cancer Biology and Research

Regulation of the Microenvironment by Rho GTPase Signaling in the Epithelium: Implications for Breast Cancer Development and Progression

Mini Review | Open Access

  • 1. Department of Biological Sciences and the Harper Cancer Research Institute, University of Notre Dame, USA
  • 2. Department of Biochemistry and Molecular Biology and the Indiana University Simon Cancer Center, Indiana University School of Medicine, USA
+ Show More - Show Less
Corresponding Authors
Tracy Vargo-Gogola, Indiana University School of Medicine, 1234 Notre Dame Avenue, South Bend IN, 46617, USA, Tel: 574-631-1587; Fax: 574-631-7821
Absract

Deregulation of Rho GTPase expression and activity levels is found in a number of  cancers, including breast cancers. Aberrant Rho GTPase signaling promotes tumorigenic  behaviors in a cell-autonomous manner. The development of conditional knockout and  overexpression mouse  of Rho GTPases and their regulators has allowed for  investigation of the impact of aberrant Rho signaling in the context of the complex  in vivo environment. These studies, including studies from our laboratory investigating  the effects of Cdc42 and p190B RhoGAP overexpression in the developing  mammary gland, indicate that altered Rho signaling in the epithelium impacts the  microenvironment. We propose that hyperactivated Rho signaling in neoplastic cells  may contribute to tumor formation by promoting the development of a pro-tumorigenic  and pro-invasive microenvironment. The availability of conditional Rho GTPase mouse  models will facilitate these studies in the future.

Citation

Gillette MR, Vargo-Gogola T (2014) Regulation of the Microenvironment by Rho GTPase Signaling in the Epithelium: Implications for Breast Cancer Development and Progression. J Cancer Biol Res 2(1): 1022

ABBREVIATIONS

Rho: Ras Homologous; GTPase: Guanosine Triphosphatase; RhoGAP: Rho GTPase activating protein; Cdc42: Cell Division Cycle 42; ECM: Extracellular Matrix; MMP: Matrix Metalloprotease; CAF: Carcinoma Associated Fibroblast; CXCL10: CXC Chemokine Ligand 10; IL-12: Interleukin-12; CSF-2: Colony Stimulating Factor-2; IFN: Interferon

INTRODUCTION

Breast cancer is the leading cancer diagnosis and the second leading cause of cancer related deaths among women in the United States [1]. The vast majority of breast cancer related deaths occur from distant metastases. While the 5-year survival rate of women diagnosed with localized breast cancer is 98.6%, this rate drops below 25% for women with distant metastases [1]. Therefore, inhibiting breast cancer development and progression to ultimately prevent metastasis offers the best hope of extending survival.

The development, progression, and metastasis of breast cancer require reciprocal tumor-stromal interactions. These interactions involve a complex interplay between tumor cells, fibroblasts, and immune cells. Secreted factors and mechanical signaling loops between these cells induce pro-tumorigenic and pro-invasive changes in the microenvironment characterized by increased Extracellular Matrix (ECM) deposition and remodeling as well as elevated expression of pro-tumorigenic growth factors and cytokines [2]. The effects of the microenvironment on breast tumor cell proliferation, invasion, metastasis, and chemoresistance have been intensely investigated [3]. Furthermore, increased infiltration and activation of fibroblasts and immune cells such as macrophages in human breast tumors correlate with poor prognosis [4,5]. However, the mechanisms by which neoplastic breast cells promote the development of the pro-tumorigenic and pro-invasive microenvironment are less well understood. Defining these mechanisms may provide new targets whose inhibition could serve to block development of the aberrant microenvironment or to restore the normal microenvironment, which naturally functions to restrain tumor formation and progression [6].

The Ras homologous (Rho) sub-family of Ras GTPases regulates a multitude of cellular processes that are important

for tumorigenesis and metastasis [7]. Elevated expression and activity levels of a number of Rho GTPases have been documented in many cancers, including invasive breast cancers [8-10]. While the cell autonomous effects of deregulated Rho signaling in cancer cells are fairly well understood [11], how aberrant Rho signaling impacts the microenvironment is now just beginning to be elucidated. This likely reflects the fact that for many years the effects of abnormal Rho signaling have been studied in isolated cells in culture. More recently, the development of conditional knockout and overexpression mouse models for several Rho family members and their regulators has allowed for investigation of the impact of altered Rho signaling in the context of the complex in vivo environment [12]. Furthermore, the increased use of three-dimensional culture models that mimic aspects of the connective tissue environment as well as heterotypic co-cultures have facilitated dissection of the cellular and molecular mechanisms governing epithelial-stromal cell cross-talk that disrupt epithelial architecture and proliferation control, and promote invasive behavior. Collectively, these models have provided tools to investigate the mechanisms by which altered Rho signaling in the epithelium may contribute to the development of the pro-tumorigenic and pro-invasive microenvironment.

Our laboratory has been interested in understanding how aberrant Rho signaling disrupts epithelial morphogenesis in the developing postnatal mammary gland as a first step towards understanding how it contributes to the development and progression of breast cancer. Most recently, we have focused on Cell Division Cycle 42 (Cdc42), one of the best-characterized members of the Rho GTPase family. Overexpression and hyperactivation of Cdc42 in human breast Invasive Ductal Carcinomas (IDC) has been demonstrated [9,10], and numerous in vitro studies and a few in vivo xenograft studies have demonstrated tumor cell autonomous functions for Cdc42 in breast tumor proliferation, migration, invasion, and metastasis [13-15]. Using a tetracycline (Tet)-regulatable Cdc42 mouse model that conditionally over expresses Cdc42 in the mammary epithelium, we have shown that Cdc42 overexpression during mammary gland development disrupts ductal morphogenesis leading to hyperbudded and trifurcated terminal end buds (TEBs, the structures that drive ductal elongation) and increased side branching [16]. Importantly, these ductal abnormalities were associated with stromal alterations reminiscent of an activated tumor microenvironment, including increased ECM deposition, elevated expression of matrix remodeling enzymes, and altered expression of pro-inflammatory cytokines (unpublished results).

A myriad of published studies investigating the effects of conditional knockout of Cdc42 have demonstrated cell type and tissue specific functions for Cdc42 in developing epithelia [17]. In addition to cell autonomous roles, loss of Cdc42 in some developing epithelia markedly impacts the adjacent microenvironment. For example, conditional knockout of Cdc42 in the developing epidermis results in epidermal hyperplasia in association with increased basement membrane protein deposition and altered epithelial-mesenchymal interactions [18]. Similarly, Cdc42 knockout in the developing lung impairs basement membrane deposition disrupting epithelial-stromal interactions [19]. Furthermore, in the developing pancreas loss of Cdc42 in the developing epithelium disrupts cell fate specification in a non-cell autonomous manner by disrupting the microenvironment [20]. Together, these studies support the notion that Cdc42 signaling in the epithelium impacts the microenvironment in developing tissues.

Interestingly, there are several parallels between our studies investigating Cdc42 and our previous studies investigating the effects of overexpression of p190B Rho GTPase activating protein (RhoGAP), and inhibitor of Rho and Rac GTPases, in the developing mammary gland. P190B elicited a similar response when conditionally overexpressed in the developing mammary epithelium of a Tet-regulatable p190B mouse model. P190B overexpressing mammary glands exhibited a disorganized, hyperbranched ductal tree in conjunction with features of aberrant stromal activation, including increased ECM deposition and elevated expression of lysyl oxidase, a collagen cross-linking enzyme [21,22]. Collectively, these studies suggest that Rho GTPase signaling in the epithelium plays a substantive role in relaying signals to the adjacent microenvironment and that its misregulation can lead to stromal activation and phenotypes that are known to contribute to the disruption of normal tissue architecture and increase invasive behavior.

Studies have shown that the development of protumorigenic and pro-invasive fibroblasts, carcinoma association fibroblasts (CAFs), occurs in a progressive manner where CAFs acquire increasingly pro-tumorigenic behaviors coincident with progression of mammary hyperplasia to adenoma to adenocarcinoma [23]. Interestingly, the pro-angiogenic and proinvasive behaviors of CAFs can be blocked by Rho kinase and myosin inhibitors, indicating a key role for cytoskeletal tension in CAF behavior. Our published data indicate that epithelial overexpression of Cdc42 or p190B increases mammary epithelial cell contractility and activation of myosin, which correlated with increased production of ECM proteins and remodeling enzymes in the developing mammary gland [16,22]. These studies suggest that deregulated Rho GTPase activity in epithelia may trigger activation of stromal fibroblasts in part by increasing tissue tension.

In addition to CAFs, the importance of macrophages during breast cancer development, invasion, and metastasis is well known [24]. Furthermore, macrophage infiltration and activation correlates with poor prognosis in breast cancer patients [5,25]. Data indicate that macrophages express pro-inflammatory cytokines during early stages of mammary tumorigenesis and switch to an anti-inflammatory phenotype during later stages of mammary tumorigenesis [26,27]. While a number of studies have provided insight into the mechanisms by which antiinflammatory macrophages promote later stages of tumor progression, less is known about the contribution of proinflammatory macrophages to the development and progression of early stage lesions. Our unpublished results indicate that stromal cells isolated from mice overexpressing Cdc42 in the developing mammary epithelium rapidly upregulate several markers of pro-inflammatory macrophages (e.g. CXCL10 and IL-12) as well as cytokines that activate pro-inflammatory phenotypes in macrophages (e.g. CSF-2 and INF-γ) following just one week of Cdc42 overexpression in the mammary epithelium. In addition, Matrix Metalloprotease (MMP) gene expression, in particular MMP-3, is rapidly upregulated in stromal cells in response to Cdc42 overexpression in the epithelium [16]. Stromal cells, including fibroblasts and macrophages, produce MMP-3, and it is a well-known inducer of secondary and tertiary branching in the developing postnatal mammary gland [28]. Thus, upregulation of stromally derived MMP-3 may be one mechanism underlying the disruption of epithelial architecture that occurs in response to Cdc42 overexpression.

In conclusion, our data and studies from other laboratories indicate that the Rho signaling network within epithelia regulates signaling loops that affect fibroblast and macrophage behavior in the adjacent microenvironment. It is attractive to speculate that Cdc42 overexpression and hyper activation in preneoplastic and transformed cells may drive tumor development and progression in part by inducing pro-tumorigenic and proinvasive changes in the microenvironment (Figure 1). While the tumor cell autonomous actions of several Rho GTPases, including Cdc42, are well known [11,13], the contribution of Rho GTPase overexpression and hyper activation in tumor cells to regulation of macrophage and fibroblast activities within the tumor microenvironment remains to be determined. Recently, there have been significant advances towards developing specific inhibitors that target Cdc42 [29,30]. Thus, targeting Cdc42 or its downstream effectors may provide a unique opportunity to simultaneously inhibit both the tumor cells and the tumor microenvironment. A deeper understanding of the contribution of epithelial Cdc42 overexpression to the development of the tumor microenvironment will facilitate the development of effective breast cancer therapeutics that target these crucial tumor-stromal interactions.

 

ACKNOWLEDGEMENTS

Funding for these studies was provided in part by an Indiana University School of Medicine Research Support Funds grant and a National Institutes of Health Clinical Translational Sciences Institute grant RR025761.

REFERENCES

1. American Cancer Society: Breast Cancer Facts and Figures 2013-2014. Atlanta: American Cancer Society, Inc 2013.

2. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009; 25: 30-38.

3. Boudreau A, van’t Veer LJ, Bissell MJ. An “elite hacker”: breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell Adh Migr. 2012; 6: 236-248.

4. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14: 518-527.

5. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1: 54-67.

6. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011; 17: 320-329.

7. Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. Front Biosci (Landmark Ed). 2011; 16: 2561-2571.

8. Tang Y, Olufemi L, Wang MT, Nie D. Role of Rho GTPases in breast cancer. Front Biosci. 2008; 13: 759-776.

9. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer. 1999; 81: 682-687.

10. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002; 87: 635-644.

11. Li H, Peyrollier K, Kilic G, Brakebusch C. Rho GTPases and cancer. Biofactors. 2014; 40: 226-235.

12. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008; 9: 690-701.

13. Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 2011; 23: 1415-1423.

14. Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti MP, Segall JD, et al. Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med. 2001; 7: 816- 830.

15. Reymond N, Im JH, Garg R, Vega FM, Borda d’Agua B, Riou P, et al. Cdc42 promotes transendothelial migration of cancer cells through β1 integrin. J Cell Biol. 2012; 199: 653-668.

16. Bray K, Gillette M, Young J, Loughran E, Hwang M, Sears JC, et al. Cdc42 overexpression induces hyperbranching in the developing mammary gland by enhancing cell migration. Breast Cancer Res. 2013; 15: R91.

17.  Melendez J, Grogg M, Zheng Y. Signaling role of Cdc42 in regulating mammalian physiology. J Biol Chem. 2011; 286: 2375-2381.

18. Wu X, Quondamatteo F, Lefever T, Czuchra A, et al. Cdc42 controls progenitor cell differentiation and beta-catenin turnover in skin. Genes Dev. 2006; 20: 571-585.

19. Wan H, Liu C, Wert SE, Xu W, Liao Y, Zheng Y, et al. CDC42 is required for structural patterning of the lung during development. Dev Biol. 2013; 374: 46-57.

20. Kesavan G, Sand FW, Greiner TU, Johansson JK, Kobberup S, Wu X, et al. Cdc42-mediated tubulogenesis controls cell specification. Cell. 2009; 139: 791-801.

21. Vargo-Gogola T, Heckman BM, Gunther EJ, Chodosh LA, Rosen JM. P190-B Rho GTPase-activating protein overexpression disrupts ductal morphogenesis and induces hyperplastic lesions in the developing mammary gland. Molecular Endocrinology. 2006; 20: 1391-1405.

22. Gillette M, Bray K, Blumenthaler A, Vargo-Gogola T. P190B RhoGAP overexpression in the developing mammary epithelium induces TGFβ-dependent fibroblast activation. PLoS One. 2013; 8: e65105.

23. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013; 15: 637-646.

24. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141: 39-51.

25. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, et al. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011; 128: 703-711.

26. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol. 2008; 180: 2011-2017.

27. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013; 35: 585-600.

28. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science. 2002; 296: 1046-1049.

29. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Nöth J, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013; 288: 8531-8543.

30. Friesland A, Zhao Y, Chen YH, Wang L, Zhou H, Lu Q. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci U S A. 2013; 110: 1261-1266

Gillette MR, Vargo-Gogola T (2014) Regulation of the Microenvironment by Rho GTPase Signaling in the Epithelium: Implications for Breast Cancer Development and Progression. J Cancer Biol Res 2(1): 1022

Received : 17 Jan 2014
Accepted : 26 Feb 2014
Published : 17 Mar 2014
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X